Pheno Therapeutics announces worldwide license from UCB to a novel program for neurodegenerative disease

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, announced today it has entered into an exclusive worldwide license agreement with UCB.